SCHEMBL24635222

SCHEMBL24635222

CCC1OC(CO)C(O)C(OC2OC(C(=O)O)C(OC)C(O)C2O)C1NC(C)=O

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 6/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ LGALS8 O00214 2/20 0.43
▸ LGALS4 P56470 1/20 0.43
▸ MDK P21741 3/20 0.42
▸ BDNF P23560 3/20 0.42
▸ PTN P21246 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ CD69 Q07108 1/20 0.41
▸ LGALS1 P09382 1/20 0.41
▸ LGALS7; LGALS7B P47929 1/20 0.41
▸ LGALS9 O00182 1/20 0.40
▸ F10 P00742 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17150140 1.00 LGALS3 (0.43) LGALS3MAPK1LGALS8LGALS4MDK
SCHEMBL12732705 0.90 LGALS3 (0.48) LGALS3MAPK1LGALS8LGALS4MDK
SCHEMBL19012241 0.89 MAPK1 (0.56) LGALS3MAPK1LGALS8LGALS4MDK
Dermatan SCHEMBL16311126 0.89 LGALS3 (0.49) LGALS3MAPK1LGALS8LGALS4MDK
Dermatan SCHEMBL18232151 0.89 LGALS3 (0.49) LGALS3MAPK1LGALS8LGALS4MDK
SCHEMBL24673751 0.89 MAPK1 (0.56) LGALS3MAPK1LGALS8LGALS4MDK
Dermatan SCHEMBL19846466 0.89 LGALS3 (0.49) LGALS3MAPK1LGALS8LGALS4MDK
Dermatan SCHEMBL13472480 0.89 LGALS3 (0.49) LGALS3MAPK1LGALS8LGALS4MDK
Dermatan SCHEMBL12691925 0.89 LGALS3 (0.49) LGALS3MAPK1LGALS8LGALS4MDK
Dermatan SCHEMBL29360360 0.89 LGALS3 (0.49) LGALS3MAPK1LGALS8LGALS4MDK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220259254-A1 TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY TAMBO, INC. 2022-08-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220259254-A1 TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY TIE1, CD74, MERTK LGALS3 350/4885MAPK1 3472/4885LGALS8 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback